BOSTON (AP) — BOSTON (AP) — Verve Therapeutics Inc. (VERV) on Tuesday reported a loss of $48.4 million in its fourth quarter.

The Boston-based company said it had a loss of 69 cents per share.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 80 cents per share.

The biotechnology firm posted revenue of $5.1 million in the period.

For the year, the company reported a loss of $200.1 million, or $3.12 per share. Revenue was reported as $11.8 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VERV at https://www.zacks.com/ap/VERV

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights. , source Associated Press News